Authors' Contributions
±, fatty liver
ADVERSE EVENTS, FATTY LIVER
F.J.F and J.Q.H participated in the conception and design of this research, explained the data, and critically revised the manuscript. All authors have read and approved the final version. All authors participated in data collection, collation, and manuscript writing. All authors are guarantors of this work and are responsible for the completeness of the data and the accuracy of data analysis.Consolidated Standards of Reporting Trials (CONSORT) diagram of participant flow through the study.(a) The number of patients with mild fatty liver at baseline, 12 weeks, and 24 weeks. (b) The number of patients with moderate and severe fatty liver at baseline, 12 weeks, and 24 weeks. (a) Plasma Baseline characteristics of study population.Abbreviations: SBP: systolic blood pressure; DBP: diastolic blood pressure. Data are Body weight, waist circumference, and liver biological indicators at different times.Note: data are mean ± standard deviation. Incidence of adverse events in each group.
Drug-related adverse events in each group.